Karan Goswami1, Javad Parvizi1, P Maxwell Courtney2. 1. The Rothman Institute at Thomas Jefferson University, 125 S 9th St. Ste 1000, Philadelphia, PA, 19107, USA. 2. The Rothman Institute at Thomas Jefferson University, 125 S 9th St. Ste 1000, Philadelphia, PA, 19107, USA. Max.Courtney@rothmaninstitute.com.
Abstract
PURPOSE OF REVIEW: Despite significant progress in recent years, the diagnosis of periprosthetic joint infection (PJI) remains a challenge and no gold standard test exists. A combination of serological, synovial, microbiological, histological, and radiological investigations is performed that are expensive, often invasive, and imperfect. Novel biomarkers and molecular methods have shown promise in recent years. The purpose of this review is to provide an update about the diagnostic recommendations for PJI and cover a selection of emerging diagnostic tools. RECENT FINDINGS: Recent literature highlights a new evidence-based definition for diagnosing hip and knee PJI that shows excellent performance on formal external multi-institutional validation. There is also increasing evidence to support the measurement of selected biomarkers in serum and synovial fluid, such as alpha-defensin, D-dimer, and interleukin-6. Finally, the emerging utility of next-generation sequencing for pathogen identification is discussed. In summary, we describe current recommendations and emerging tests for the diagnosis of PJI. Residual limitations and directions for future research are also discussed.
PURPOSE OF REVIEW: Despite significant progress in recent years, the diagnosis of periprosthetic joint infection (PJI) remains a challenge and no gold standard test exists. A combination of serological, synovial, microbiological, histological, and radiological investigations is performed that are expensive, often invasive, and imperfect. Novel biomarkers and molecular methods have shown promise in recent years. The purpose of this review is to provide an update about the diagnostic recommendations for PJI and cover a selection of emerging diagnostic tools. RECENT FINDINGS: Recent literature highlights a new evidence-based definition for diagnosing hip and knee PJI that shows excellent performance on formal external multi-institutional validation. There is also increasing evidence to support the measurement of selected biomarkers in serum and synovial fluid, such as alpha-defensin, D-dimer, and interleukin-6. Finally, the emerging utility of next-generation sequencing for pathogen identification is discussed. In summary, we describe current recommendations and emerging tests for the diagnosis of PJI. Residual limitations and directions for future research are also discussed.
Authors: J Bohannon Mason; Thomas K Fehring; Susan M Odum; William L Griffin; Donna S Nussman Journal: J Arthroplasty Date: 2003-12 Impact factor: 4.757
Authors: Hany Bedair; Nicholas Ting; Christina Jacovides; Arjun Saxena; Mario Moric; Javad Parvizi; Craig J Della Valle Journal: Clin Orthop Relat Res Date: 2011-01 Impact factor: 4.176
Authors: Steven M Kurtz; Kevin L Ong; Jordana Schmier; Fionna Mowat; Khaled Saleh; Eva Dybvik; Johan Kärrholm; Göran Garellick; Leif I Havelin; Ove Furnes; Henrik Malchau; Edmund Lau Journal: J Bone Joint Surg Am Date: 2007-10 Impact factor: 5.284
Authors: Paul H Yi; Michael B Cross; Mario Moric; Brett R Levine; Scott M Sporer; Wayne G Paprosky; Joshua J Jacobs; Craig J Della Valle Journal: Clin Orthop Relat Res Date: 2015-02 Impact factor: 4.176
Authors: Peter M Keller; Yvonne Achermann; Aleš Chrdle; Tomáš Trnka; David Musil; Sandro F Fucentese; Peter Bode Journal: J Clin Microbiol Date: 2019-07-26 Impact factor: 5.948
Authors: Beverly L Hersh; Neel B Shah; Scott D Rothenberger; Jason P Zlotnicki; Brian A Klatt; Kenneth L Urish Journal: J Arthroplasty Date: 2019-06-28 Impact factor: 4.757
Authors: Thao L Masters; Aditya V Bhagwate; Mrunal K Dehankar; Kerryl E Greenwood-Quaintance; Matthew P Abdel; Jay N Mandrekar; Robin Patel Journal: Gene Date: 2022-03-17 Impact factor: 3.688